Persistent URL of this record https://hdl.handle.net/1887/3502348
Documents
-
- Download
- European_Journal_of_Pharmaceutical_Sciences_2022
- Accepted Manuscript
-
open access
- Full text at publishers site
In Collections
This item can be found in the following collections:
The PBPK LeiCNS-PK3.0 framework predicts Nirmatrelvir (but not Remdesivir or Molnupiravir) to achieve effective concentrations against SARS-CoV-2 in human brain cells
- All authors
- Saleh, M.A.A.E.W.; Hirasawa, M.; Sun, M.; Berfin, G.; Elassaiss, J.; Lange, E.C.M. de
- Date
- 2022-11-30
- Volume
- 181
- Advanced Publication
- Yes